

News Release



Name Change of European Subsidiary

May 8, 2013, Osaka, Japan—Santen Pharmaceutical Co., Ltd. (Code: 4536:JP, “Santen”) announces that the name of one of its European subsidiaries has been changed from Novagali Pharma S.A.S. to Santen S.A.S., effective April 25, 2013.

Novagali Pharma S.A.S. became a wholly-owned subsidiary of Santen after 100% of its shares were acquired by Santen in January 2012. The company is involved in advanced research development and pharmaceutical development activities, and is currently conducting research and development of ethical pharmaceutical products in the area of ophthalmology. The change in name to Santen S.A.S. was determined in order to: further enhance synergetic effects within the Santen Group by widely using the “Santen” name; promote the presence of the Santen brand throughout the European market; and therefore further accelerate the development and launch of new products that are needed by the market and patients in Europe.

Company profile

Name:	Santen S.A.S.
Location:	1 rue Pierre Fontaine, Genavenir IV, F-91058 Evry cedex, France
Paid-in capital:	€1,489,942
Equity ownership:	100% by Santen Holdings EU B.V.
Representative:	Jérôme Martinez, President
Business:	Clinical development and marketing of pharmaceuticals

X X X